HCP

Further Information

SmPC

Dymista^®^ a novel formulation

Dymista^®^ a novel formulation

Dymista® is a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate.2,3

The recommended daily dose is one spray in each nostril twice a day
(morning and evening).2

More effective than current first line therapy in reducing both nasal and ocular symptoms.3,4

  1. Dymista Summary of Product Characteristics.
  2. Meltzer et al. Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis. Int Arch Allergy Immunol 2013;161:369–37
  3. Price P, Bousquet J, Hellings P, et al. Abstract presented at SERIN, Leuven, Belgium, 21-23 March 2013

Dymista® is indicated for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.2

  1. Dymista Summary of Product Characteristics.